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1. Introduction 
Type 1 diabetes (T1D) is an autoimmune disease characterized by immune destruction of 
insulin-producing pancreatic β cells. This leads to dysfunctional regulation of blood glucose 
levels in T1D patients. The destruction of β cells of Langerhans islets is caused by infiltration 
of dendritic cells, macrophages and T lymphocytes. The destruction of β cells starts with an 
autoimmune process that is followed by massive destruction of β cells later on. 
Autoantibodies against T1D-specific antigens are present in serum and can be detected in 
the early stage of the disease (Ounisis-Benkalha & Polychronakos, 2008). There are several 
main types of T1D autoantibodies: islet antibodies, antibodies to insulin (IAA), glutamic 
acid decarboxilase (GADA) and tyrosine phosphatise IA-2. In the last few years antibodies 
to zinc transporter (ZnT8) have been added to this group (Mehers & Gillespie, 2008). It is 
generally accepted that T1D occurs as a result of genetic and environmental factors when 
presence of many alleles combined with effects of numerous environmental factors lead to 
disease development (Pociot et al., 2010). Research of T1D genetic basis and environmental 
factors has increased dramatically in the last two decades. Today it is considered that beside 
HLA region on chromosome 6q21 that contributes approximately with 40% to T1D 
development, more than 50 non-HLA genes significantly increase the risk of T1D occurrence 
(MacFarlane et al., 2009, Ziegler et al., 2010; Concannon et al., 2010). The final aim of genetic 
research is integration with clinical practice, which is expected once the main understanding 
of genetic etiology of T1D is achieved. Translation to clinics includes development of 
genetic-based diagnostic tests, population screening methods and prevention strategies, and 
finally, development of new treatments and therapies (Manolio et al., 2009).  
2. Genetic studies 
There are two main approaches in dissecting T1D genetic background: linkage analysis and 
association analysis (Figure 1). Linkage analysis is based on simple Mendelian inheritance 
and it uses affected relatives (typically siblings) to identify regions on chromosomes that are 
shared more frequently than expected by chance. Since affected siblings are relatively rare in 
T1D, linkage studies have been performed in somewhat unique subgroup of families with 
T1D (Concannon et al., 2009). In general, samples are genotyped for a modestly dense panel 
of markers, typically microsatellites, to search for linked alleles i.e. alleles that are inherited 
together. Regions in the genome with accumulating evidence of linkage are further fine 
mapped, which means that additional markers are typed in the same chromosomal region,  
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Fig. 1. Linkage analysis tests for the co-segregation of alleles within family members 
whereas association analysis searches for the difference in allele frequency between 
unrelated groups of affected and unaffected individuals or within families. Adapted from 
Concannon et al., 2009. 
 
 
Fig. 2. Relation of risk allele frequencies, effect sizes (odds ratios) and feasibility of 
identifying risk variants by common genetic tests. Generally, linkage studies are better in 
indentifying low-frequency alleles with larger effect sizes, whereas association studies are 
more effective in identifying common variants with small to moderate effects. Adapted from 
McCarthy et al., 2008 & Manolio et. al., 2009. 
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in order to narrow down regions associated with disease. Linkage analyses are most 
effective in identifying rare alleles with large effect sizes (Figure 2) (Concannon et al., 2009). 
On the other hand, common alleles with modest and small effect sizes can be identified 
through association analysis. Association studies test for association of genotyped marker 
(typically single nucleotide polymorphism, SNP) with the disease of interest in a case-
control or family-based sample. These studies rely on the assumption that investigated allele 
is associated with disease if it differs in frequency between two investigated groups of 
individuals. Tested polymorphism is usually not the causative one but it will show an 
association if it is in linkage disequilibrium (LD) with an unknown causative, risk or 
protective, variant. Human genome is divided into regions of high and low LD, and if allele 
resides in the region of high LD that means that many SNPs from the same region will be 
inherited together and therefore reflect one another. This means that genotyping of only 
limited, but carefully selected, set of SNPs can actually capture a majority of information 
within tested gene region (Lander, 2011). 
For the last decade the most common design of association analysis used to be candidate 
gene approach that searches for differences in allele frequencies in specifically selected 
genes between affected and healthy groups of individuals or affected subjects and their 
parents. There are few general limits of candidate gene studies that include modest sample 
sizes, limited number of investigated variants, the fact that selection of genes/variants is 
often based on inadequate understanding of biological pathways and, most importantly, 
observed associations are usually difficult to replicate (Manolio et al., 2009). However, just 
few years ago a complete dominance in association analyses design was taken by genome-
wide association studies (GWAS) approach. These are hypothesis free studies that usually 
test between 300,000 up to 1 million directly genotyped SNPs that capture substantial 
proportion of common genetic variation of the genome (McCarthy et al. 2008). The 
methodology behind the GWAS is the same as in any association study and that is to map 
susceptibility variants through identification of associations between allele (genotype) 
frequency and disease status (McCarthy et al. 2008). The development of both, high-
throughput genotyping platforms and a catalogue of human variation by International 
HapMap Project (http://hapmap.ncbi.nlm.nih.gov/) and The 1000 Genomes project 
(http://www.1000genomes.org/) have made possible high utilization of GWAS. In 
addition, development of imputation methods that infer missing genetic variants enabled 
inclusion and comparison of different GWAS in large-scale meta-analysis framework 
(Marchini & Howie, 2010).  Also, huge collaborative international projects such as The Type 
1 Diabetes Genetics Consortium (T1DGC) (https://www.t1dgc.org/home.cfm) have put 
efforts to collect and systemise data from several thousand T1D affected and healthy 
individuals worldwide in order to identify genes contributing to an individual’s risk for 
T1D susceptibility. Overall, the combination of linkage, association and large-scale GWAS 
approaches provided evidence of genetic contribution of many common and rare alleles 
with wide range of effect sizes to the T1D development.  
2.1 Linkage analysis approach 
Genetic linkage studies have shown the biggest success in discovering genetic loci 
underlying monogenic disorders where risk factors, even rare in frequency, have large 
effects and often lead to change in amino acid sequence (Smith & Newton-Cheh 2009). In 
complex diseases, such as T1D, situation is less straightforward since there are loci of small, 
modest and large effect sizes contributing to the disease (Concannon et al., 2009; Kere, 2010). 
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Several linkage analyses of T1D provided evidence for linkage between the HLA region on 
chromosome 6p21 and T1D. There were also other non-HLA loci findings but these were not 
consistently replicated among studies, mostly because of limited sample sizes. T1DGC 
conducted linkage meta-analysis of most of T1D genome-wide linkage studies and showed 
strong evidence of linkage with HLA class II genes encoding HLA-DR and HLA-DQ. In 
addition, this study demonstrated supporting evidence of linkage of additional genes within 
HLA region and small number of other regions in the genome (Concannon et al., 2009).  
2.2 Association analysis approach 
2.2.1 Case–control design  
Case-control design is one of the most common association study designs.  Case-control 
study compares two groups of individuals, one with the disease (cases) and the other 
without disease (controls). It is assumed that cases have higher prevalence of susceptibility 
alleles for disease of interest than controls and that susceptibility alleles can be detected 
through direct comparison of allele frequencies between two groups (McCarthy et al. 2008). 
A lot of attention is given to case ascertainment to minimize phenotypic heterogeneity. In 
addition, study power can be improved by selection of cases, for example to those with the 
extremes of phenotypes (McCarthy et al. 2008). Since it is observed that incident rates of T1D 
highly increase in the very young group of children, an early age of disease onset could be 
an example of extreme T1D phenotype and enrichment of those cases in the sample set is 
likely to improve power (McCarthy et al. 2008; Maahs et al. 2010). 
In genetic epidemiological studies a lot of attention is given to control selection. Controls are 
matched with cases by ethnicity to avoid problems of population stratification that may 
result with spurious associations (false positives). This means that controls are selected from 
the same population, preferably from the same region, as cases (Zondervan & Cardon 2007). 
Nowadays, with the genome-wide data, it is possible to estimate the level of relatedness 
among individuals and, also, the matching of cases and controls by ancestry (Anderson et al. 
2010). Principal component analysis is one of the most common methods that enables 
clustering of individuals by ancestry (Figure 3). To further reduce stratification within the 
sample set, controls can also be matched to cases by age, sex and environmental factors. 
Usually, association analyses are adjusted for covariates with strong impact on phenotype to 
reduce non-genetic contribution to phenotype variation (Smith & Newton-Cheh 2009).   
2.2.2 Family-based design 
Family-based association studies, most commonly in the form of parent–offspring trios, use 
another analytical approach to test for association. To make assumptions on association with 
the disease these studies examine the transmission of alleles from heterozygous parents to 
affected offspring that is observed more frequently than expected by chance (Smith & 
Newton-Cheh 2009). Since these studies are conducted within families they offer a 
protection from population stratification but they also rely on informative parent–offspring 
trios which usually reduce the effective sample size, thus power as well (McCarthy et al. 
2008; Smith & Newton-Cheh 2009). Family-based studies are particularly useful in finding 
variants underlying relatively rare phenotypes that segregate within families. Also, these 
studies have advantages when age of disease onset is low, as in the case of T1D, because it 
enables easier collection of many family members (Smith & Newton-Cheh 2009). 
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Fig. 3. Principal component analysis of samples deriving from population of interest (POP) 
and 11 HapMap phase II populations (CEU - Utah residents with Northern and Western 
European ancestry from the CEPH collection; TSI - Toscans in Italy; MEX - Mexican ancestry 
in Los Angeles; GIH - Gujarati Indians in Houston; CHB - Han Chinese in Beijing, China; 
CHD - Chinese in Metropolitan Denver; JPT - Japanese in Tokyo, YRI - Yoruba in Ibadan, 
Nigeria; LWK - Luhya in Webuye, Kenya; ASW - African ancestry in Southwest USA; MKK 
- Maasai in Kinyawa, Kenya) 
2.2.3 Genome-wide association studies (GWAS) and meta-analyses 
Rationale underlying GWAS is the ‘common disease, common variant’ hypothesis. It is 
believed that both, common and rare variants, contribute to complex disease risk. However, 
GWAS are generally powered only to detect association of common variants (allelic variants 
present in more than 5% of the population) with modest to large effect sizes (Manolio et al., 
2009).  GWAS are not designed to identify multiple rare mutations within a gene (Kere, 
2010). 
Because of the modest sample sizes individual GWAS have limited power to detect all 
associations underlying complex diseases. Increase in sample size achieved by combination 
of statistical evidence of individual studies through meta-analysis approach can improve 
study power and raise a discovery of susceptibility loci. Nowdays, a majority of new genetic 
findings underlying complex traits are found through meta-analysis approach. Since 
different studies differ in design, sample collection, genotyping platform and analysis 
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methodology, one of the most important prerequisites for meta-analysis is capability to 
uniform study results. Most genotyping platforms have different representation of genetic 
markers and harmonisation of studies through expansion of SNP coverage can be achieved 
by imputation processes. Imputation infers and fills in missing genotypes on the basis of 
HapMap, the 1000 Genomes or other reference panels to allow different studies to analyse 
the same set of common SNPs (de Bakker et al., 2010). The biggest meta-analysis for T1D 
combined results from two studies and included total of 7,514 cases and 9,045 reference 
samples. This study identified another 18 regions associated with T1D that suggested novel 
candidate genes such as IL10, IL19, IL20, GLIS3, CD69 and IL27 (Barrett et al., 2009). 
2.3 Other types of genetic research 
There are many other types of genetic research that contribute to understanding of complex 
disease mechanisms. Many of these studies use knowledge on susceptible genetic variation 
accumulated through linkage and association studies. Identified variants are usually 
additionally analysed for gene-gene and gene-environment interactions. Also, it is well 
known that genes interact through complex molecular networks and integrating the prior 
knowledge of biological pathways of genes of interest may increase a chance to find genes 
involved in disease development. These pathway-based analyses use different software 
packages that search through variety of web-based databases and take into account the 
existing data on biological pathways of investigated genes (Wang et al., 2010). Cross-
disorder overlap is another search that looks for evidence of potential overlapping regions 
of the genome affecting various different diseases, such as T1D and other autoimmune traits 
(Eyre et al. 2010). All these supplementary analyses help in elucidating genetic contribution 
in complex disease development. 
There are functional studies that also use data derived from genetic analyses. Most 
commonly performed ones are gene expression analyses that may investigate susceptible 
genes/gene variants in different tissues or investigate them under different environmental 
stimuli. Combining the information on gene expression profiles and alternate splicing sites 
across a range of human tissues together with genetic mapping for the same samples will be 
valuable in deciphering the roles of genetic variants (McCarthy et al., 2008). Genetical 
genomics analysis also offers new means in understanding the genetic architecture of gene 
expression (Cui et al., 2010) 
2.4 Finding the missing heritability 
GWAS have identified more than 50 genetic variants associated with T1D. However, just 
like in most other complex traits, associated variants explain only a small proportion of 
heritability of T1D (λs~5, whereas it is estimated to be 15) and have rather small effect on 
disease risk (Clayton, 2009). The remaining missing heritability can be explained in several 
different ways such as an influence of much larger number of common variants of smaller 
effect sizes that still need to be identified, an influence of rare variants of modest and small 
effect sizes that have not yet been discovered because of their underrepresentation in the 
current genotyping platforms and because of underpowered sample sizes, an influence of 
structural variants that are also poorly captured by existing platforms and generally low 
power to detect gene–gene and gene-environment interactions (Manolio et al., 2009). Sample 
size is generally one of the major limiting factors for discovery of common alleles with small 
effect sizes. Augmenting the number of investigated individuals through meta-analysis 
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approach to more than tens of thousands of individuals is another way for discovery of new 
genetic loci (Lander, 2011). On the other hand sequencing is the best way for discovering 
rare and structural variants such as copy number variants, inversions, translocations, 
microsatellite repeat expansions, insertions of new sequence and complex rearrangements 
(Manolio et al., 2009). Because of immense decrease in price, sequencing is becoming a 
common practice and next generation sequencing (exon or whole-genome sequencing) 
might provide many clues for missing heritability. The 1000 Genomes Project 
(http://www.1000genomes.org/) aims to provide a complete catalogue of human genome 
sequence variation and the pilot phase of the project already identified around 15 million 
SNPs, 1 million short insertions and deletions and 20,000 structural variants (The 1000 
Genomes Project Consortium et al., 2010). Most of these variants were previously unknown 
and will provide a foundation for future genetic research of human diseases, including T1D. 
Also, sequencing of individuals with extreme phenotypes, for example individuals with the 
extreme age of T1D diagnosis, might provide important findings because it is thought that 
they carry more deleterious, loss-of-function mutations (Romeo et al., 2007). 
It is also thought that some of the missing heritability might be discovered by conducting 
studies in populations of non European ancestry. Most genetic studies have been limited to 
European populations even it is known that genetic variation is highest in the populations 
of recent African ancestry. These studies might prove useful in detecting rare variants 
associations and narrowing down associated regions due to smaller LD windows 
(International HapMap Consortium et al., 2007). Family studies and isolated populations are 
another sample sets that might help in identifying missing heritability due to their 
enrichment of unique genetic variants (Sabatti et al., 2009). 
2.5 Prevention, diagnostics and clinical application of genetic findings 
Genetic research of complex diseases aims to improve understanding of biological and 
physiological pathways involved in disease etiology. The main goal is integration of newly 
accumulated knowledge with clinical practice by development of more effective means of 
diagnosis, prevention, treatment and response to therapies. Identification of predictive 
variants for considerable proportion of disease, even with identification of many other risk 
variants with smaller effect sizes, is very challenging (Manolio et al., 2009).  The biggest 
influence for T1D development is carried by HLA loci and it is shown that only few HLA 
SNPs capture most of the heritability of T1D risk that is attributable to HLA associations 
(Clayton, 2009). There is substantial genetic risk to T1D that can be attributable to yet 
undiscovered loci and it is assumed that the majority of these loci will have smaller effects 
than those loci which have already been discovered (Clayton, 2009). So far, genetic 
prediction for T1D is modest and it is still not reaching criteria required for a targeted 
disease prevention strategy (Clayton, 2009).  However, it is believed that a small proportion 
of population at the highest risk will be identifiable and the development of diagnostic and 
targeted prevention strategies for those individuals will be feasible. These diagnostic and 
interventional strategies will require more accurate genetic prediction and it is necessary 
that they are developed through ethical, safe, effective and individualized approach 
(Manolio et al., 2009; Clayton, 2009). One of suggested ways to discover individuals at risk is 
through population screening which means genotyping specific genetic variants, whole-
genome typing and whole-genome sequencing of entire population (Manolio et al., 2009; 
Pharoah et al., 2008). Figure 4 shows the ways of translation of genetic findings into clinical 
practice and disease management. 
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Fig. 4. Translation of genetic information into clinical practice. Adapted from McCarthy et 
al. 2008. 
3. Genetic background of T1D 
3.1 Rare monogenetic forms of T1D 
Very rare form of autoimmune diabetes is monogenetic diabetes, which means that it is 
caused by mutation of a single gene. In such cases, diabetes occurs as part of multiple set of 
autoimmune diseases. One of them is known as the immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome in which a function of 
regulatory T cells is impaired (van Belle et al., 2011).  It occurs as a result of mutations of 
FOXP3, the master gene for normal functioning of regulatory T cells (Wang et al., 2010). 
About 80% of children with IPEX syndrome develop autoimmune diabetes at an early age 
(van Belle et al., 2011).  Another example of multiple autoimmune disease is autoimmune 
polyendocrine syndrome type 1 (APS-1) or autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED) (van Belle et al., 2011). The main cause of APECED 
development is mutations in the autoimmune regulator (AIRE) protein (Villaseñor et al. 
2005). Lack of AIRE protein decreases the expression of insulin and other peripheral 
molecules in the thymus. This allows effector T cells escape to the periphery and prevent 
their negative selection in the thymus through apoptosis (Liston et al., 2004). About 20% of 
APS1 or APECED patients develop T1D (van Belle et al., 2011).  Although the number of 
patients with this monogenic form of T1D is almost negligible, these findings indicate the 
high impact of immune status on the disease occurrence (van Belle et al., 2011).  
3.2 Family history of T1D 
Over 85% of T1D patients do not have positive family history of T1D, however there is a 6% 
of disease clustering among siblings. Siblings have 15 times greater chance of developing 
T1D in comparison with the general population which gives strong evidence of the genetic 
background of this disease. The pattern of inheritance seems very complicated, and disease 
development further depends on the triggers from the environment. Long-term monitoring 
showed that the concordance rate of inheritance is greater than 50% in monozygous twins, 
while it is 6-10% in dizygous twins, which is similar to that of siblings. Interestingly, the 
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siblings who share both identical haplotypes of DR3/DR4 HLA class II region, which shows 
highest susceptibility to T1D, have a higher risk of disease development than those who 
share only one or no haplotypes of that region. (Steck & Rewers 2011).  
3.3 HLA 
First and consistent evidence of HLA gene contribution to the disease was provided by 
linkage analyses and further confirmed by association analyses. HLA genes contribute with 
approximately 40% of genetic risk to T1D development (MacFarlane et al., 2009). The 
proteins encoded by HLA genes are cell-surface proteins grouped in class I (A, B and C) and 
class II (DP, DQ and DR) of HLA region on chromosome 6p21 (Figure 5). Both groups of 
proteins are essential in self and non-self immune recognition. The proteins encoded by the 
HLA class I genes are single chain proteins that present intracellular antigen to CD8+ T killer 
cells while proteins encoded by HLA class II are built of two chains and present extracellular 
antigen to CD4+ T helper cells (Ounisis-Benkalha & Polychronakos, 2008). It is considered 
today that the HLA region class II has the strongest input in the development of T1D, which 
has been deeply investigated in the past several decades (van Belle et al., 2011). HLA DR4 
and DR3 class II haplotypes are of particular importance in the T1D development. Even 
greater risk of T1D development have individuals with genetic combinations of two 
susceptible alleles, DR3/DR4. HLA region on chromosome 6p21.3 comprises more than 200 
 
 
Fig. 5. HLA region on hromosome 6p21.3. Adapted from Mehers & Gillespie, 2008. 
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genes that are in high LD. Therefore, it is difficult to determine which gene gives the 
observed effect. It is considered that haplotypes of high risk for T1D are DRB1*0401-
DQA1*0301-DQB1*0302 and DRB1*0301-DQA1*0501-DQB1*0201(Mehers & Gillespie, 2008; 
Skrodeniene et al., 2010). Antigen-presenting cells (APC) carry HLA class II molecules that 
bind key T1D autoantigens such as preproinsulin, insulinoma associated antigen 2, glutamic 
acid decarboxilase (GAD) and zinc transporter (ZnT8) and present them to thymocites in the 
thymus. Strongly self-reactive thymocites die by apoptosis, negative selection that 
eliminates 98% of thymocytes. Only 2% of thymocytes that have low affinity migrate as 
mature T cells in the periphery where they develop into CD4+ and CD8+ T cells. CD4+ T cells 
are helper cells to CD8+ T killer cells in the processes of destruction of pancreatic islet β cells 
(Figure 6). It is believed that the most important autoantigen in the onset of T1D is 
preproinsulin, whose N-terminal signal peptide and the peptidase cleavage site is 
recognised by CD8+ T killer cells. The proteins encoded by HLA class I, HLA-A and HLA-B 
exert smaller effects in the pathogenesis of T1D. Proteins encoded by class I HLA genes are 
expressed on nucleated cells, often in the pancreatic insulin-producing β cells. These 
proteins present antigens directly to the CD8+ T killer cells (Figure 6) (Ounisis-Benkalha & 
Polychronakos, 2008; Todd, 2010; Pociot et al., 2010; Blueston et al., 2010; van Belle et al., 
2011).  However, it was observed that some HLA haplotype combinations have protective 
association with T1D. It is believed that haplotype DR15-DQ6, which was found in  about 
20% of the general population and even less than 1% of patients with T1D has protective 
effect (Ounisis-Benkalha & Polychronakos, 2008). 
3.4 Other non-HLA pathways 
Linkage analyses additionally pointed to linkage of some non-HLA loci but without 
consistent replication. Candidate-gene association studies have further confirmed HLA loci 
as the major T1D genetic factors but also identified four other T1D susceptibility loci: gene 
for insulin (INS), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), protein tyrosine 
phosphatise, non-receptor type 22 (lymphoid) (PTPN22) and interleukin 2 receptor, alpha 
(IL2RA) (Bell et al., 1984; Nisticò et al., 1996; Bottini et al., 2004; Lowe et al., 2007). 
The first strong non-HLA association with T1D was shown with polymorphisms within the 
INS gene (Bell et al., 1984). Variable number of tandem repeats (VNTR) composed of 14-15 
bp tandem repeat sequence (ACAGGGGTGTGGGG) is located 596 bp upstream of the INS 
gene on chromosome 11p15 and regulates gene transcription (Ounissi-Benkalha & 
Polychronakos, 2008). Alleles of this region are divided into three classes with respect to the 
number of consecutive VNTRs: class I VNTR alleles (short, 26-63 repeats), class II VNTR 
alleles (63-140 repeats) and class III VNTR alleles (long, 141-209) (Durinovic-Bello et al., 
2010). They correlate with INS mRNA production in pancreas and thymus. Class I alleles of 
the INS VNTR increase the risk of T1D and have been associated with high mRNA levels in 
pancreas and low levels in thymus. Class III alleles are associated with 20% lower mRNA 
than class I in pancreas but two to three times higher mRNA levels in thymus and therefore 
are considered to be protective. It seems that high levels of proinsuline in the thymus may 
stimulate negative selection (dying by apoptosis) of insulin specific T-lymphocits crucial in 
the pathogenesis of T1D. On the other hand it is believed that lower levels of proinsuline in 
thymus affect the positive selection of T cells in the thymus, migration of CD4+ proinsulin 
specific T cells in the periphery, that increase risk to T1D. In that way, the genetically regulated 
selection mechanisms affect the selection of autoreactive cells in the immune response to 
autoantigenes (Todd, 2010; Pociot et al., 2010; Ounissi-Benkalha & Polychronakos, 2008). 
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Fig. 6. The development of an autoimmune reaction in T1D. Adapted from Ounisis-
Benkalha & Polychronakos, 2008. 
In 1996 CTLA4 gene located on chromosome 2q33 was confirmed as another T1D 
susceptibility gene (Nistico L et al., 1996.). CTLA4 protein is a co-stimulatory receptor on the 
cell surface of CD4+ T cells. It binds B7 ligands of APCs that activate main component of the 
co-receptor, CD28. In the same time intracellular part of the CTLA4 interact with 
intracellular domain of CD3 receptor and start phosphorylation of the several downstream 
target molecules. Consequently, this leads to activation of T cells after their binding to HLA 
molecules on APCs (Figure 6) (Ounissi-Benkalha & Polychronakos, 2008). Reduction of the 
CTLA4 protein in CD4+ T cells increases susceptibility to T1D (Todd, 2010; Pociot et al., 
2010). The A49G polymorphism in exone 1 causes substitution of an alanine with a 
threonine in the signal sequence of CTLA4 protein that leads to incorrect glycosylation of 
mutant protein and reduction of its expression on T-cell surface. Conversely, C318T 
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polymorphism of the CTLA4 promoter gene region causes higher promoter activity and 
increases the amount of CTL4 protein on the T cell surface. Therefore, it can be considered as 
protective polymorphism of this gene (Ounissi-Benkalha & Polychronakos, 2008). 
More recently in 2004, PTPN22 gene located on chromosome 1q13 that encodes lymphoid 
tyrosine phosphatase was recognized as further T1D susceptibility gene (Bottini et al., 2004). 
Lymphoid tyrosine phosphatise “Lip” inhibits T cell receptor (TCR) signal transduction and 
causes inhibition of CD4+ T-cell activation (Figure 6). The Lyp inhibitory function is 
enhanced by its interaction with C-terminal Src tyrosine kinase (Csk). T1D is associated with 
a polymorphism at position 1858 by replacing the C to T, which leads to the substitution of 
arginine to tryptophan at position 620 of Lyp protein (R620W) (Ounissi-Benkalha & 
Polychronakos, 2008; Mehers & Gillespie, 2008; Todd, 2010; Pociot et al., 2010). The Lyp 
interaction with tyrosine kinase Csk occurs just in the 620 region. A 620W allele interacts 
less strongly with Csk than 620R allele. A 620W homozygous shows increased inhibition of 
TCR signalling, reduces CD4+ T cell activation thus resulting in increased autoimmunity 
(Todd, 2010; Pociot et al., 2010; Ziegler et al., 2010).  
Another strongly associated gene, IL2RA located on chromosome 10p15 that encodes alpha 
chain (CD25) molecules of IL-2 receptor has been reported as T1D associated gene (Vella et 
al. 2005).  The CD25 is responsible for binding of IL-2 and proliferation of regulatory T cell 
and consequently, it affects their function in inhibition of effector T cells and autoimmune 
disease (Figure 6).  T1D-predisponding alleles of IL2RA gene correlate with lower amounts 
of CD25 on the surface of the regulatory T cells which are suppressors of autoreactivity and 
that can be important in regulation of T-cell proliferation by an immunogenic stimulus 
(Ounissi-Benkalha & Polychronakos, 2008; Mehers & Gillespie, 2008; Todd, 2010; Pociot et 
al., 2010). 
Since 2001 a significant number of GWA studies have been reported. Data from The 
International Type 1 Diabetes Genetics Consortium (T1DGC) collected through multiple 
genome-wide association studies are available to the scientific community by request. 
Recently, GWAS and large scale meta-analyses identified more than 40 loci that affect the 
risk of developing T1D (Table 1.) (Barrett et al., 2009, Pociot et al., 2010). The analysis 
included 7.514 cases and 9.045 control samples. Fifteen of these regions have been 
previously reported as regions associated with T1D susceptibility. Eighteen additional 
regions showed significant association with T1D and several of them contain new candidate 
genes of possible relevance to T1D (IL10, IL19, IL20, GLIS3, CD69 and IL27) (Pociot et al., 
2010). Most of the listed genes mediate the immune response, some exert their functions in 
the process of destruction of pancreatic β cells and some have a dual role (Pociot et al., 2010).  
A list of SNPs and genes associated with T1D is presented in Table 1. 
 
SNP Chromosome OR minor allele Gene of interest 
rs2476601 1p13.2 2.05 PTPN22 
rs2269241 1p31.3 1.10 PGM1 
rs2816316 1q31.2 0.89 RGS1 
rs3024505 1q32.1 0.84 IL10 (CNTN2)  
rs1534422 2p25.1 1.08 (gene desert) 
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SNP Chromosome OR minor allele Gene of interest 
rs917997 2q12.1 0.83 IL18RAP 
rs1990760 2q24.2 0.86 IFIH1 
rs3087243 2q33.2 0.88 CTLA4 
rs11711054 3p21.31 0.85 CCR5 
rs10517086 4p15.2 1.09 (gene desert) 
rs4505848 4q27 1.13 IL2 
rs6897932 5q13.2 0.89 IL7R 
rs9268645 6p21.32 6.8 MHC 
rs11755527 6q15 1.13 BACH2 
rs9388489 6q22.32 1.17 C6orf173 
rs2327832 6q23.3 0.90 TNFAIP3 
rs1738074 6q25.3 0.92 TAGAP 
rs7804356 7p15.2 0.88 SKAP2 
rs4948088 7p12.1 0.77 COBL 
rs7020673 9p24.2 0.88 GLIS3 
rs12251307 10p15.1 1.61 IL2RA 
rs11258747 10p15.1 0.84 PRKCQ 
rs10509540 10q23.31 0.75 RNLS 
rs7111341 11p15.5 2.38 INS (TH) 
rs4763879 12p13 1.09 CD69 
rs2292239 12q13.2 1.31 ERBB3 
rs1678536 12q13.3.  Multiple (MMP19-LOCx-GSTPP) 
rs3184504 12q24.12 1.28 SH2B3 
rs1465788 14q24.1 0.86 C14orf181 
rs4900384 14q32.2 1.09 (0; gene desert) 
rs3825932 15q25.1 0.86 CTSH 
rs12708716 16p13.13 0.81 CLEC16A 
rs12444268 16p12.3 1.10 UMOD
rs4788084 16p11.2 0.86 IL27 (NUPR1)
rs7202877 16q23.1 1.28 CTRB1
rs16956936 17p13.1 0.92 DNAH2
rs2290400 17q12 0.87 ORMDL3 (GSDML3) 
rs7221109 17q21.2 0.95 SMARCE1
rs1893217 18p11.21 1.28 PTPN2
rs763361 18q22.2 1.16 CD226
rs425105 19q13.32 0.86 PRKD2
rs2281808 20p13 0.90 SIRPG
rs11203203 21q22.3 1.13 UBASH3A
rs5753037 22q12.2 1.10 LOC729980/HORMAD2 
rs229541 22q13.1 1.12 C1QTNF6
rs2664170 Xq28 1.16 GAB3
Table 1. SNPs associated with T1D according to Pociot et al. 2010 & Barret et al 2008. 
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Additional functional studies provided evidence of causality of several genes within 
established loci, such as several cytokines and their receptors (IL10, IL2, IL27, IL7R, CCR5, 
SH2B3, IL18RAP), immunomodulatory molecules (IFIH1, TLR7-TLR8, TAGAP) and other 
types of proteins  (PTPN2, GLIS3). However, for the majority of associated regions the most 
likely causal gene still needs to be identified (Todd, 2010). IFIH1 gene on chromosome 
2q24.2 encodes intracellular pathogen receptor, MDA5, responsible for binding of viral 
RNA. This binding stimulates the production of type 1 interferon that could enhance 
cytotoxic activity of T cells on pancreatic β cells. TLR7-TLR8 genes on chromosome Xp22.2 
also encode intracellular receptors for viral RNA. This may explain induction of 
autoimmune destruction of β cells by numerous viral infections that may raise type 1 
interferon levels (Todd, 2010; Pociot et al., 2010; Concannon et al., 2010). GLIS3 acts as both 
transcriptional activator and repressor and is specifically involved in the development of 
pancreatic β cells. Mutations in this gene have been associated with a rare syndrome of 
neonatal diabetes and congenital hypothyroidism (Grant SF et al., 2009). It is the only gene 
that shows overlap between T1D and T2D that may be due to its function in the 
development and/or function of β cells (Todd, 2010).  
There are more than 300 candidate genes that are in LD with T1D associated genetic regions. 
Also, it has been shown that at least 10 T1D associated regions do not contain a functional 
candidate gene which suggests that distant, long-range gene regulation might underly some 
of the observed associations. The main focus of current research is to identify causal risk 
genes and to understand how they influence the disease (Todd, 2010; Pociot et al., 2010). 
T1DGC is involved in the research of many autoimmune diseases since it is believed that 
many of them share common genetic background. A genotyping assay called ImmunoChip, 
that includes ~200 000 SNPs that are expected to be involved or were previously associated 
with immune reactions, was developed in order to disentangle the genetic background of 
various autoimmune diseases including T1D (Pociot et al., 2010). 
3.5 Genetic markers in prediction and prevention of T1D 
Recently, several population studies attempted to stratify children at birth according to their 
predisposition for T1D development by examining their HLA genotypes and insulin gene 
polymorphisms. Denver, Germany and Finland studies showed that children with the high 
risk HLA genotypes or polymorphisms within the insulin gene have about 50% higher risk 
of developing T1D-specific antibodies by the age of 5 (Barker et al., 2004, Walter et al., 2003, 
Hummel et al, 2004, Steck & Rewers, 2011). Assessment of risk can be extended by including 
other polymorphisms of susceptible genes for T1D development as well as family history of 
diabetes (Steck & Rewers, 2011). The application of preventive therapy would be focused on 
those individuals who have the highest genetic predisposition for the T1D development. 
Animal model of mucosal administration of insulin in the prevention of autoimmune 
diabetes has proven to be safe. Mucosal administration of insulin as a self-antigen stimulates 
a protective immune response that has the potential to affect the destructive immune 
response that would otherwise follow. Low doses of autoantigenes induce regulatory T cells 
that release inhibitory cytokines, while high doses destroy autoreactive effector T cells. Pre-
POINT (Primary Oral Insulin) Trial in siblings with the high genetic risk for T1D, involving 
several European populations, Canada and USA, plans to investigate such treatment. 
Children aged 18 months and 7 years with a family history and genetic predisposition to 
T1D will be enrolled in the study. Conduction  of study is planned in two steps: –step one - 
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genetic screening and determination of serum antibodies: step two - recruitment  of selected 
children and treatment (test of four doses of insulin). As the effect depends on the dose and 
route at which insulin is administred in primary mucosal insulin therapy, goal of this study 
is to find a safe dose (applied orally or intranasal) that will induce an immune response to 
insulin. Pre-POINT studies should continue with POINT study with the determinate set 
dose. The main objective of this study is to determine whether the use of oral insulin can 
prevent or delay the onset of T1D in individuals with high genetic risk (Steck & Rewers, 
2011, Achenbac et al, 2008). 
4. Epigenetics 
There is a significant increase in the incidence of T1D in the last 50 years that is mainly 
explained by changes in the environment. It is believed that environmental factors can affect 
epigenetic mechanisms of candidate genes expression and development of T1D. Epigenetic 
mechanisms encouraged with environmental factors can cause identical genotypes to exhibit 
different phenotypes. The proposed environmental factors that can trigger an autoimmune 
process involve nutrition and viruses. Nutrients that may trigger epigenetic mechanisms are 
considered to be substances that provide a methyl group (methionine, choline) or cofactors 
(folic acid, vitamin B12 and pyridoxal phosphate) required for DNA and histone 
methylation (Hewagama & Richardson, 2009). Actually, there are three ways in which 
phenotype can be altered by epigenetic modifications of gene expression: methylation of 
DNA, histone modification or activation of micro-RNA. It is well known that silencing of 
gene expression can be achieved by methylation of cytosine in CpG dinucleotides. 
Acetylation, methylation, phosphorilation and ubiquitination of histones modify the 
chromatin conformation, which can stimulate or silent gene expression. MicroRNAs bind to 
mRNA causing degradation before the translation in protein. These mechanisms that alter 
gene expression may influence development and function of immune system, as well as 
development, function and recovery of pancreatic β cells. Differentiation of T-helper cells is 
regulated by a complex epigenetic control. Critical epigenetic process in T-helper cells 
differentiation is DNA methylation, which can affect the expression of specific cytokines 
(interferons, interleukins) and encourage autoreactivity. Development, function and 
regeneration of pancreatic β cells largely depend on the genetic profile that will be 
expressed. Progressive decline of pancreatic β cells in type 1 and type 2 diabetes is strongly 
associated with the expression of genes responsible for the development and function of β 
cells.  It is shown that the activity of the insulin gene is dependent on mechanisms of histone 
acetylation and methylation. It was also shown that the blood glucose concentration can 
affect the activity of enzymes that regulate the methylation process, but this seems to be 
associated with type 2 diabetes (MacFarlane et al., 2009). 
5. Environment 
Numerous environmental factors are implicated in T1D disease development in genetically 
susceptible individuals. Many of these factors act in uterine life, infancy and early childhood 
and are namely associated with viral infections and diet (Norris, 2010; Roivainen & Klingel, 
2010).  
Viral infections are considered to be the major environmental factors predisposing to T1D.  
Rotaviruses, adenoviruses, retroviruses, reoviruses, cytomegalovirus, Epstein-Barr virus, 
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mumps virus and rubella virus are the ones that have been implicated in T1D pathogenesis 
but the most risk ones are human enteroviral (HEV) intestinal infections. Coxsackievirus 
and echovirus serotypes of HEV infections, are highly cytolitic and can cause β cell cytolysis 
and activate innate and adaptive immune system but can also activate autoreactive T cells 
(Roivainen & Klingel, 2010). A recent study examined autoimmune microbiome for T1D and 
came out with conclusion that microbiomes of healthy children differ to those of children 
that develop T1D later in their lives. This means that microbiome could be used as bacterial 
marker for the early T1D diagnosis. Also, the “healthy” microbiome could be used in the 
prevention of T1D development in children at genetically high risk of developing disease 
(Giongo et al. 2011). 
The maternal diet during pregnancy, such as vegetable and vitamin D consumption, and 
wheat, cow’s milk and omega-3 fatty acids early exposures in life are speculated to have a role 
in the aetiology of the disease. Introduction of cow’s milk and meat prior 6 months of age have 
shown to have risk effects. Likewise, cereal, gluten or wheat antigens may cause an aberrant 
response in developing immune system. Some other factors may have protective effects 
against T1D development, such as early introduction of vegetable oil and high omega-3 fatty 
acid intake (Norris, 2010). Huge international collaborative effort, The Environmental 
Determinants of Diabetes in the Young (TEDDY) (http://teddy.epi.usf.edu/), was developed 
with the aim of identifying environmental factors that modify risk for T1D (TEDDY, 2008). 
It is generally considered that environmental and behavioural factors have stronger effects 
on disease development than genetic loci itself, but it is very hard to accurately identify and 
measure them. The largest effects are expected from gene and environment interaction in 
individuals that are genetically at high-risk for disease development (Clayton, 2009). 
6. Conclusion 
The main genetic predisposition for developing T1D comes from the HLA region. There are 
currently identified additional ~50 non-HLA loci that predispose to risk of T1D.  It is 
expected that the remaining T1D susceptible loci will be explained by additional common 
and rare genetic variants, structural polymorphisms, gene-gene and gene-environment 
interactions and epigenetic events. A role of associated genes and their protein products in 
disease aetiology is under intense investigation but the candidacy of many loci implicate to 
the combined effect of adaptive and innate immune action in insulin-producing β cell 
destruction. Further genetic studies performed on much bigger datasets comprising tens of 
thousands of individuals, detailed genetic mapping, genotype-phenotype correlation 
studies and other functional studies will be crucial in deciphering a complete genetic 
architecture of T1D and understanding the disease mechanisms.  The main goal of genetic 
research is to link research findings with advances in therapy such as screening of 
individuals and implementation of preventive measures to those with high genetic 
predisposition to T1D and development of new, more efficient treatments and therapies. 
Detection of major pathways in the development of T1D opens up new therapeutic targets, 
development of more efficient treatments and individual approaches to patients.  
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